Related Experiment Videos
Insights
Coronary arterial spasm, a cause of myocardial ischemia, is now recognized in various heart conditions. Understanding vasospasm is crucial for developing effective treatments for ischemic heart disease.
Area of Science:
- Cardiology
- Vascular Biology
- Ischemic Heart Disease
Background:
- Coronary arterial spasm has been a suspected cause of myocardial ischemia for over a century.
- Clinical research significantly advanced following Prinzmetal's 1959 work, highlighting vasospasm's role in ischemic heart disease.
- Vasospasm is now understood to affect patients with and without significant coronary artery disease.
Purpose of the Study:
- To review the clinical significance and implications of coronary arterial spasm.
- To explore the association of vasospasm with various ischemic heart disease syndromes.
- To emphasize the importance of developing therapeutic agents for vasospasm prevention.
Main Methods:
- Literature review of historical and contemporary research on coronary vasospasm.
- Analysis of clinical observations linking vasospasm to angina, myocardial infarction, and arrhythmias.
- Synthesis of evidence regarding the role of vasospasm in both atherosclerotic and non-atherosclerotic coronary conditions.
Main Results:
- Coronary vasospasm is implicated in stable angina, unstable angina, and acute myocardial infarction.
- Vasospasm can occur in individuals with significant coronary atherosclerosis as well as those with normal or minimally narrowed coronary arteries.
- Documented complications of coronary vasospasm include symptomatic arrhythmias such as bradycardia, heart block, and ventricular tachyarrhythmias.
Conclusions:
- Coronary arterial spasm is a significant factor in a wide spectrum of ischemic heart disease manifestations.
- The recognition of vasospasm's broad clinical impact underscores the need for effective spasm-inhibiting therapies.
- Further research and development of therapeutic agents to prevent coronary vasospasm are clinically important.
Abstract:
Coronary arterial spasm has been postulated to be a cause of myocardial ischemia for over 100 years. It was not until the work of Prinzmetal et al in 1959, however, that major clinical attention and research began to be addressed to the role of vasospasm in the manifestations of ischemic heart disease. It is now known that spasm may be clinically important in patients with significant underlying atherosclerotic coronary artery disease as well as in patients with anatomically normal or subcritically stenosed coronary vessels. Research has suggested that spasm may be associated with symptoms of stable resting and/or exertional angina pectoris and that it almost certainly plays a role in the pathogenesis of unstable angina pectoris and acute myocardial infarction. Symptomatic arrhythmias, including sinus bradycardia, heart block, and ventricular tachyarrhythmias, have been documented to complicate coronary vasospasm. Given the potential importance of coronary arterial spasm in so many different ischemic heart disease syndromes, the development of therapeutic agents that may prevent spasm has obvious clinical importance.